EMMA · Emmaus Life Sciences, Inc.
$0.03
+0.01 (+22.99%)
At close · Aug 21
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because the Company's existing cash balance and anticipated cash flows cannot satisfy its current debt and ongoing obligations, combined with the uncommitted nature of the Company's financing plans, there is substantial doubt about the Company’s ability to continue as a going concern for 12 months from the date that these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$2.25M
Shares
70.19M
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2023-01-31 | New | Pharmaceuticals | $235,000 | $0 | 06b |
| 2023-01-20 | New | Pharmaceuticals | $34,000,000 | $0 | 06c |
| 2022-06-30 | New | Pharmaceuticals | $220,000 | $110,000 | 06b |
| 2021-02-16 | New | Pharmaceuticals | $17,000,000 | $1,920,000 | 06c |
| 2020-10-09 | Amendment | Pharmaceuticals | $3,840,300 | $3,840,300 | 06c |
| 2020-10-07 | Amendment | Pharmaceuticals | $3,680,800 | $3,680,800 | 06c |
| 2020-10-07 | New | Pharmaceuticals | $3,680,800 | $0 | 06c |
| 2020-08-07 | New | Pharmaceuticals | $1,895,000 | $947,600 | 06c |
Showing 1–8 of 8 filings